Increased Expression of LYNX1 in Ovarian Serous Cystadenocarcinoma Predicts Poor Prognosis

Table 4

Univariate and multivariate Cox proportional hazard analysis of LYNX1 expression and disease-specific survival (DSS) for patients with ovarian serous cystadenocarcinoma (OVs) in the validation cohort.

Characteristics	Univariate analysis		Multivariate analysis
	HR (95% CI)	value	HR (95% CI)	value
Clinical stage (stage I/II vs. stage III/IV)	2.244 (0.922–5.462)	0.075	2.26 (0.551–9.271)	0.258
Primary therapy outcome (SD-PD vs. PR-CR)	0.295 (0.199–0.439)	<0.001	0.348 (0.227–0.535)	<0.001
Cancer status (tumor free vs. with tumor)	15.22 (6.731–34.413)	<0.001	19.489 (6.144–61.818)	<0.001
Histologic grade (G1G2 vs. G3G4)	1.313 (0.833–2.07)	0.24
Tumor residual disease (NRD vs. RD)	2.559 (1.572–4.166)	<0.001	1.141 (0.671–1.938)	0.626
Anatomic neoplasm subdivision (unilateral vs. bilateral)	1.034 (0.747–1.431)	0.841
Age (<60 vs. ≥60)	1.248 (0.944–1.65)	0.12
LYNX1 (low vs. high)	1.393 (1.053–1.845)	0.02	1.566 (1.13–2.17)	0.007

SD: stable disease; PD: progressive disease; PR: partial remission; CR: complete remission; NRD: no residual disease; RD: residual disease; HR: hazard ratio; CI: confidence interval.